Lan Rinda Coffman

Dr. Lan Rinda Coffman

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
WWWei Wang
Wei Wang
MKMary Ann Knovich
Mary Ann Knovich
LCLan Rinda Coffman
Lan Rinda Coffman
FTFrank M. Torti
Frank M. Torti
STSuzy V. Torti
Suzy V. Torti

1 May 2009 in Blood Reviews
Verified
Journal Article
Closed access
MKMary Ann Knovich
Mary Ann Knovich
JSJonathan A. Storey
Jonathan A. Storey
LCLan Rinda Coffman
Lan Rinda Coffman
STSuzy V. Torti
Suzy V. Torti
FTFrank M. Torti
Frank M. Torti

7 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ARAyana T. Ruffin
Ayana T. Ruffin
ACAnthony R. Cillo
Anthony R. Cillo
TTTracy Tabib
Tracy Tabib
ALAngen Liu
Angen Liu
SOSayali Onkar
Sayali Onkar
TBTullia C. Bruno
Tullia C. Bruno
Current immunotherapy paradigms aim to reinvigorate CD8+ T cells, but the contribution of humoral immunity to antitumor immunity remains understudied. Here, we demonstrate that in head and neck squamous cell carcinoma (HNSCC) caused by human papillomavirus infection (HPV+), patients have transcriptional signatures of germinal center (GC) tumor infiltrating B cells (TIL-Bs) and spatial organization of immune cells consistent with tertiary lymphoid structures (TLS) with GCs, both of which correlate with favorable outcome. GC TIL-Bs in HPV+ HNSCC are characterized by distinct waves of gene expression consistent with dark zone, light zone and a transitional state of GC B cells. Semaphorin 4a expression is enhanced on GC TIL-Bs present in TLS of HPV+ HNSCC and during the differentiation of TIL-Bs. Our study suggests that therapeutics to enhance TIL-B responses in HNSCC should be prioritized in future studies to determine if they can complement current T cell mediated immunotherapies.

1 July 2019 in Translational Research
Verified
Journal Article
Open access
CCChelsea Chandler
Chelsea Chandler
TLTianshi Liu
Tianshi Liu
RBRonald Buckanovich
Ronald Buckanovich
LCLan Rinda Coffman
Lan Rinda Coffman
Cancer-associated fibrosis is a critical component of the tumor microenvironment (TME) which significantly impacts cancer behavior. However, there is significant controversy regarding fibrosis as a predominantly tumor promoting or tumor suppressing factor. Cells essential to the generation of tissue fibrosis such as fibroblasts and mesenchymal stem cells (MSCs) have dual phenotypes dependent upon their independence or association with cancer cells. Cancer-associated fibroblasts and cancer-associated MSCs have unique molecular profiles which facilitate cancer cell cross talk, influence extracellular matrix deposition, and direct the immune system to generate a protumorigenic environment. In contrast, normal tissue fibroblasts and MSCs are important in restraining cancer initiation, influencing epithelial cell differentiation, and limiting cancer cell invasion. We propose this apparent dichotomy of function is due to (1) cancer mediated stromal reprogramming; (2) tissue stromal source; (3) unique subtypes of fibrosis; and (4) the impact of fibrosis on other TME elements. First, as cancer progresses, tumor cells influence their surrounding stroma to move from a cancer restraining phenotype into a cancer supportive role. Second, cancer has specific organ tropism, thus stroma derived from preferred metastatic organs support growth while less preferred metastatic tissues do not. Third, there are subtypes of fibrosis which have unique function to support or inhibit cancer growth. Fourth, depleting fibrosis influences other TME components which drive the cancer response. Collectively, this review highlights the complexity of cancer-associated fibrosis and supports a dual function of fibrosis which evolves during the continuum of cancer growth.

30 October 2011 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LMLance Miller
Lance Miller
LCLan Rinda Coffman
Lan Rinda Coffman
JCJeff W. Chou
Jeff W. Chou
MBMichael Black
Michael Black
JBJonas Bergh
Jonas Bergh
FTFrank M. Torti
Frank M. Torti
Changes in iron regulation characterize the malignant state. However, the pathways that effect these changes and their specific impact on prognosis remain poorly understood. We capitalized on publicly available microarray datasets comprising 674 breast cancer cases to systematically investigate how expression of genes related to iron metabolism is linked to breast cancer prognosis. Of 61 genes involved in iron regulation, 49% were statistically significantly associated with distant metastasis-free survival. Cases were divided into test and training cohorts, and the supervised principal component method was used to stratify cases into risk groups. Optimal risk stratification was achieved with a model comprising 16 genes, which we term the iron regulatory gene signature (IRGS). Multivariable analysis revealed that the IRGS contributes information not captured by conventional prognostic indicators (HR = 1.61; 95% confidence interval: 1.16–2.24; P = 0.004). The IRGS successfully stratified homogeneously treated patients, including ER+ patients treated with tamoxifen monotherapy, both with (P = 0.006) and without (P = 0.03) lymph node metastases. To test whether multiple pathways were embedded within the IRGS, we evaluated the performance of two gene dyads with known roles in iron biology in ER+ patients treated with tamoxifen monotherapy (n = 371). For both dyads, gene combinations that minimized intracellular iron content [anti-import: TFRCLow/HFEHigh; or pro-export: SLC40A1 (ferroportin)High/HAMPLow] were associated with favorable prognosis (P < 0.005). Although the clinical utility of the IRGS will require further evaluation, its ability to both identify high-risk patients within traditionally low-risk groups and low-risk patients within high-risk groups has the potential to affect therapeutic decision making. Cancer Res; 71(21); 6728–37. ©2011 AACR.

13 January 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
LCLan Rinda Coffman
Lan Rinda Coffman
DPDerek Parsonage
Derek Parsonage
RDRalph D'AGostino
Ralph D'AGostino
FTFrank M. Torti
Frank M. Torti
STSuzy V. Torti
Suzy V. Torti
Angiogenesis, the synthesis of new blood vessels from preexisting vessels, plays a critical role in normal wound healing and tumor growth. HKa (cleaved high molecular weight kininogen) is an endogenous inhibitor of angiogenesis formed by the cleavage of kininogen on endothelial cells. Ferritin is a protein principally known for its central role in iron storage. Here, we demonstrate that ferritin binds to HKa with high affinity ( K d 13 nM). Further, ferritin antagonizes the antiangiogenic effects of HKa, enhancing the migration, assembly, and survival of HKa-treated endothelial cells. Effects of ferritin were independent of its iron content. Peptide mapping revealed that ferritin binds to a 22-aa subdomain of HKa that is critical to its antiangiogenic activity. In vivo, ferritin opposed HKa's antiangiogenic effects in a human prostate cancer xenograft, restoring tumor-dependent vessel growth. Ferritin-mediated regulation of angiogenesis represents a new angiogenic regulatory pathway, and identifies a new role for ferritin in cell biology.